Redwood, California-based Tranquis Therapeutics, is a clinical-stage biopharmaceutical company that is developing a portfolio of small molecule drugs capable of reprogramming dysfunctional myeloid immune cells to restore normal cell homeostasis and function. Their therapeutic candidates can “switch” dysfunctional microglia and monocytes back to a more functional state by targeting master regulators of cell energy metabolism, such as PGC1α. Tranquis’s lead product is TQS-168, which is currently in Phase one of clinical trials is being developed a a treatment for amyotrophic lateral sclerosis (ALS). TQS -168 has shown benefits in various animal models of neurodegenerative disease, including ALS. In vitro, TQS-168 also shows specific immunomodulatory effects in cell lines and white blood cells from patients with ALS and may therefore have other indications.